Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years

Table 1 Comparison of patient demographics between groups

Variable	Denosumab (n = 120)	ZA (n = 122)	P – value
Age (years)	64.9 ± 3.01	65.4 ± 3.44	0.19^*a
Menopause age	53.1 ± 1.82	52.9 ± 1.78	0.43^*a
Pathological types, No.			0.92^*b
Invasive ductal carcinoma	97	98
Other pathological types	23	24
Tumor staging			0.95^*c
I	53	57
II	46	40
III	21	25
BMI (kg/m²)	24.4 ± 2.34	23.9 ± 2.36	0.11^*a
BMD	−2.30 ± 0.21	−2.33 ± 0.29	0.37^*a
Personal history of fractures	15/120	19/122	0.49^*b
Family history of fractures	17/120	18/122	0.90^*b

^* No statistically significant values. ^a Analysed using an Independent-Samples t-test; ^b Analysed using the Chi-square test; ^c Analysed using the Mann-Whitney test. ZA: zoledronic acid; SSEs: symptomatic skeletal events; BMI: body mass index; BMD: bone mineral density

ISSN: 1471-2474